Vir Biotechnology Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 367

Employees

  • Stock Symbol
  • VIR

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $8.39
  • (As of Friday Closing)

Vir Biotechnology General Information

Description

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Contact Information

Website
www.vir.bio
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1800 Owens Street
  • Suite 900
  • San Francisco, CA 94158
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1800 Owens Street
  • Suite 900
  • San Francisco, CA 94158
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vir Biotechnology Stock Performance

As of 20-Nov-2026, Vir Biotechnology’s stock price is $8.39. Its current market cap is $1.56B with 186M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.39 $8.87 $5.45 - $14.38 $1.56B 186M 2.44M -$1.19

Vir Biotechnology Financials Summary

As of 30-Sep-2026, Vir Biotechnology has a trailing 12-month revenue of $302M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,452,382 432,586 209,205 (215,593)
Revenue 302,454 66,520 63,712 39,494
EBITDA (206,720) (466,328) (580,355) (695,733)
Net Income (184,790) (437,987) (521,960) (615,061)
Total Assets 1,111,855 1,002,823 1,398,813 1,919,060
Total Debt 90,775 97,852 97,891 124,540
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vir Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vir Biotechnology‘s full profile, request access.

Request a free trial

Vir Biotechnology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vir Biotechnology‘s full profile, request access.

Request a free trial

Vir Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering
Drug Discovery
San Francisco, CA
367 As of 2025

South San Francisco, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vir Biotechnology Competitors (81)

One of Vir Biotechnology’s 81 competitors is Rigel Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rigel Pharmaceuticals Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Precigen Formerly VC-backed Germantown, MD
Adimab Venture Capital-Backed Lebanon, NH
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 81 competitors. Get the full list »

Vir Biotechnology Patents

Vir Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213138-A1 Pharmaceutical formulations for antibody delivery Pending 01-Apr-2025
WO-2026207501-A1 Therapeutic uses of egfr targeted bispecific polypeptides Pending 28-Mar-2025
WO-2026198954-A1 Methods and compositions for the treatment and prevention of marburg virus infection Pending 21-Mar-2025
WO-2026156215-A1 Combination therapy for treating hepatitis d virus (hdv) infection Pending 17-Jan-2025
WO-2026136923-A1 Therapeutic uses of her-2 targeted bispecific polypeptides Pending 20-Dec-2024 C07K16/32
To view Vir Biotechnology’s complete patent history, request access »

Vir Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vir Biotechnology Investments & Acquisitions (4)

Vir Biotechnology’s most recent deal was a Merger/Acquisition with Agenovir. The deal was made on 09-May-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Agenovir 09-May-2018 Merger/Acquisition Biotechnology
Humabs BioMed 25-Sep-2017 Merger/Acquisition Other Pharmaceuticals and Biotechnology
TomegaVax 01-Jan-2017 Later Stage VC Drug Discovery
TomegaVax 01-Jan-2016 Merger/Acquisition Drug Discovery
To view Vir Biotechnology’s complete investments and acquisitions history, request access »

Vir Biotechnology ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.86 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vir Biotechnology’s complete esg history, request access »

Vir Biotechnology Exits (2)

Vir Biotechnology’s most recent exit was on 01-Jan-2017 from TomegaVax. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
TomegaVax 01-Jan-2017 Completed
  • 4 buyers
TomegaVax 01-Jan-2016 Merger/Acquisition Completed
To view Vir Biotechnology’s complete exits history, request access »

Vir Biotechnology FAQs

  • When was Vir Biotechnology founded?

    Vir Biotechnology was founded in 2016.

  • Where is Vir Biotechnology headquartered?

    Vir Biotechnology is headquartered in San Francisco, CA.

  • What is the size of Vir Biotechnology?

    Vir Biotechnology has 367 total employees.

  • What industry is Vir Biotechnology in?

    Vir Biotechnology’s primary industry is Drug Discovery.

  • Is Vir Biotechnology a private or public company?

    Vir Biotechnology is a Public company.

  • What is Vir Biotechnology’s stock symbol?

    The ticker symbol for Vir Biotechnology is VIR.

  • What is the current stock price of Vir Biotechnology?

    As of 20-Nov-2026 the stock price of Vir Biotechnology is $8.39.

  • What is the current market cap of Vir Biotechnology?

    The current market capitalization of Vir Biotechnology is $1.56B.

  • What is Vir Biotechnology’s current revenue?

    The trailing twelve month revenue for Vir Biotechnology is $302M.

  • Who are Vir Biotechnology’s competitors?

    Rigel Pharmaceuticals, Adaptimmune Therapeutics, Precigen, Adimab, and Sorrento Therapeutics are some of the 81 competitors of Vir Biotechnology.

  • What is Vir Biotechnology’s annual earnings per share (EPS)?

    Vir Biotechnology’s EPS for 12 months was -$1.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process